Patents by Inventor Kenneth W. Dobie

Kenneth W. Dobie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulation of G protein-coupled receptor RE2 expression
    Publication number: 20040091871
    Abstract: Compounds, compositions and methods are provided for modulating the expression of G protein-coupled receptor RE2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding G protein-coupled receptor RE2. Methods of using these compounds for modulation of G protein-coupled receptor RE2 expression and for diagnosis and treatment of disease associated with expression of G protein-coupled receptor RE2 are provided.
    Type: Application
    Filed: November 11, 2002
    Publication date: May 13, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Ming-Yi Chiang, Kenneth W. Dobie
  • Modulation of ADAM9 expression
    Publication number: 20040092466
    Abstract: Compounds, compositions and methods are provided for modulating the expression of ADAM9. The compositions comprise oligonucleotides, targeted to nucleic acid encoding ADAM9. Methods of using these compounds for modulation of ADAM9 expression and for diagnosis and treatment of disease associated with expression of ADAM9 are provided.
    Type: Application
    Filed: November 11, 2002
    Publication date: May 13, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Nicholas M. Dean, Kenneth W. Dobie
  • Modulation of phosphodiesterase 1B expression
    Publication number: 20040092461
    Abstract: Compounds, compositions and methods are provided for modulating the expression of phosphodiesterase 1B. The compositions comprise oligonucleotides, targeted to nucleic acid encoding phosphodiesterase 1B. Methods of using these compounds for modulation of phosphodiesterase 1B expression and for diagnosis and treatment of disease associated with expression of phosphodiesterase 1B are provided.
    Type: Application
    Filed: November 11, 2002
    Publication date: May 13, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Kenneth W. Dobie
  • Modulation of mitogen-activated protein kinase kinase kinase 11 expression
    Publication number: 20040092464
    Abstract: Compounds, compositions and methods are provided for modulating the expression of mitogen-activated protein kinase kinase kinase 11. The compositions comprise oligonucleotides, targeted to nucleic acid encoding mitogen-activated protein kinase kinase kinase 11. Methods of using these compounds for modulation of mitogen-activated protein kinase kinase kinase 11 expression and for diagnosis and treatment of disease associated with expression of mitogen-activated protein kinase kinase kinase 11 are provided.
    Type: Application
    Filed: November 11, 2002
    Publication date: May 13, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Nicholas M. Dean, Kenneth W. Dobie
  • Modulation of endothelial differentiation gene 2 expression
    Publication number: 20040092462
    Abstract: Compounds, compositions and methods are provided for modulating the expression of endothelial differentiation gene 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding endothelial differentiation gene 2. Methods of using these compounds for modulation of endothelial differentiation gene 2 expression and for diagnosis and treatment of disease associated with expression of endothelial differentiation gene 2 are provided.
    Type: Application
    Filed: November 13, 2002
    Publication date: May 13, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Nicholas M. Dean, Kenneth W. Dobie
  • Modulation of huntingtin interacting protein 1 expression
    Publication number: 20040092465
    Abstract: Compounds, compositions and methods are provided for modulating the expression of huntingtin interacting protein 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding huntingtin interacting protein 1. Methods of using these compounds for modulation of huntingtin interacting protein 1 expression and for diagnosis and treatment of disease associated with expression of huntingtin interacting protein 1 are provided.
    Type: Application
    Filed: November 11, 2002
    Publication date: May 13, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventor: Kenneth W. Dobie
  • Antisense modulation of cyclin-dependent kinase 6 expression
    Publication number: 20040087523
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of cyclin-dependent kinase 6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding cyclin-dependent kinase 6. Methods of using these compounds for modulation of cyclin-dependent kinase 6 expression and for treatment of diseases associated with expression of cyclin-dependent kinase 6 are provided.
    Type: Application
    Filed: July 31, 2002
    Publication date: May 6, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Susan M. Freier, Kenneth W. Dobie
  • Antisense modulation of KOX 1 expression
    Publication number: 20040087536
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of KOX 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding KOX 1. Methods of using these compounds for modulation of KOX 1 expression and for treatment of diseases associated with expression of KOX 1 are provided.
    Type: Application
    Filed: August 19, 2003
    Publication date: May 6, 2004
    Inventors: Kenneth W. Dobie, Susan M. Freier
  • Antisense modulation of histone deacetylase 2 expression
    Publication number: 20040077578
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of histone deacetylase 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding histone deacetylase 2. Methods of using these compounds for modulation of histone deacetylase 2 expression and for treatment of diseases associated with expression of histone deacetylase 2 are provided.
    Type: Application
    Filed: September 2, 2003
    Publication date: April 22, 2004
    Inventors: Brett P. Monia, Kenneth W. Dobie
  • Antisense modulation of fatty acid synthase expression
    Publication number: 20040077570
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of fatty acid synthase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding fatty acid synthase. Methods of using these compounds for modulation of fatty acid synthase expression and for treatment of diseases associated with expression of fatty acid synthase are provided.
    Type: Application
    Filed: October 17, 2002
    Publication date: April 22, 2004
    Inventors: Susan M. Freier, Kenneth W. Dobie, Sanjay Bhanot
  • Antisense modulation of mucin 1, transmembrane expression
    Patent number: 6716627
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of mucin 1, transmembrane. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding mucin 1, transmembrane. Methods of using these compounds for modulation of mucin 1, transmembrane expression and for treatment of diseases associated with expression of mucin 1, transmembrane are provided.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: April 6, 2004
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventor: Kenneth W. Dobie
  • Antisense modulation of phosphoinositide-3-kinase, regulatory subunit 4, P150 expression
    Publication number: 20040063657
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of phosphoinositide-3-kinase, regulatory subunit 4, p150. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding phosphoinositide-3-kinase, regulatory subunit 4, p150. Methods of using these compounds for modulation of phosphoinositide-3-kinase, regulatory subunit 4, p150 expression and for treatment of diseases associated with expression of phosphoinositide-3-kinase, regulatory subunit 4, p150 are provided.
    Type: Application
    Filed: September 18, 2003
    Publication date: April 1, 2004
    Inventors: Susan M. Freier, Kenneth W. Dobie
  • Antisense modulation of phosphotyrosyl phosphatase activator expression
    Publication number: 20040023906
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of phosphotyrosyl phosphatase activator. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding phosphotyrosyl phosphatase activator. Methods of using these compounds for modulation of phosphotyrosyl phosphatase activator expression and for treatment of diseases associated with expression of phosphotyrosyl phosphatase activator are provided.
    Type: Application
    Filed: August 1, 2002
    Publication date: February 5, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Nicholas M. Dean, Kenneth W. Dobie
  • Antisense modulation of Ran GTPase activating protein 1 expression
    Publication number: 20040022765
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Ran GTPase activating protein 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Ran GTPase activating protein 1. Methods of using these compounds for modulation of Ran GTPase activating protein 1 expression and for treatment of diseases associated with expression of Ran GTPase activating protein 1 are provided.
    Type: Application
    Filed: July 31, 2002
    Publication date: February 5, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Kenneth W. Dobie
  • Antisense modulation of LAR expression
    Publication number: 20040023905
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of LAR. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding LAR. Methods of using these compounds for modulation of LAR expression and for treatment of diseases associated with expression of LAR are provided.
    Type: Application
    Filed: July 31, 2002
    Publication date: February 5, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Sanjay Bhanot, Kenneth W. Dobie, Susan M. Freier
  • Antisense modulation of G protein-coupled receptor 6 expression
    Publication number: 20040023380
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of G protein-coupled receptor 6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G protein-coupled receptor 6. Methods of using these compounds for modulation of G protein-coupled receptor 6 expression and for treatment of diseases associated with expression of G protein-coupled receptor 6 are provided.
    Type: Application
    Filed: July 31, 2002
    Publication date: February 5, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Kenneth W. Dobie
  • Antisense modulation of G protein-coupled receptor 12 expression
    Publication number: 20040023384
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of G protein-coupled receptor 12. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G protein-coupled receptor 12. Methods of using these compounds for modulation of G protein-coupled receptor 12 expression and for treatment of diseases associated with expression of G protein-coupled receptor 12 are provided.
    Type: Application
    Filed: July 31, 2002
    Publication date: February 5, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Kenneth W. Dobie
  • Antisense modulation of PTPRA expression
    Publication number: 20040023904
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PTPRA. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTPRA. Methods of using these compounds for modulation of PTPRA expression and for treatment of diseases associated with expression of PTPRA are provided.
    Type: Application
    Filed: July 31, 2002
    Publication date: February 5, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Lex M. Cowsert, Susan M. Freier, Kenneth W. Dobie
  • Antisense modulation of requiem expression
    Publication number: 20040023385
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of requiem. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding requiem. Methods of using these compounds for modulation of requiem expression and for treatment of diseases associated with expression of requiem are provided.
    Type: Application
    Filed: August 5, 2002
    Publication date: February 5, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Kenneth W. Dobie
  • Antisense modulation of hepatoma-derived growth factor expression
    Publication number: 20040023379
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of hepatoma-derived growth factor. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding hepatoma-derived growth factor. Methods of using these compounds for modulation of hepatoma-derived growth factor expression and for treatment of diseases associated with expression of hepatoma-derived growth factor are provided.
    Type: Application
    Filed: July 31, 2002
    Publication date: February 5, 2004
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Kenneth W. Dobie